Compare BSRR & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | PRME |
|---|---|---|
| Founded | 1977 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 536.4M |
| IPO Year | 2001 | 2022 |
| Metric | BSRR | PRME |
|---|---|---|
| Price | $38.10 | $2.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $37.00 | $7.56 |
| AVG Volume (30 Days) | 46.6K | ★ 2.2M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 10.28 | ★ 18.18 |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $11.74 | $7.06 |
| Revenue Next Year | $3.63 | $47.01 |
| P/E Ratio | $39.70 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $26.49 | $1.18 |
| 52 Week High | $38.87 | $6.94 |
| Indicator | BSRR | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 39.24 |
| Support Level | $36.00 | N/A |
| Resistance Level | $38.45 | $3.97 |
| Average True Range (ATR) | 0.89 | 0.24 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 75.53 | 31.15 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.